Market research

Parkinson's Disease Monitoring Device Market

The Parkinson's Disease Monitoring Device Market is projected to grow by USD 440.91 million at a CAGR of 9.24% by 2032.

Explore licensesfrom $3,939

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

16report chapters

Public research overviewHow we research Research team

Parkinson’s Disease Monitoring Devices: Executive Overview

Parkinson’s disease monitoring devices support the longitudinal assessment of motor symptoms, treatment response, mobility, sleep, and daily functioning. The field includes wearable sensors, smartphone-enabled assessments, home-based measurement tools, and clinically integrated digital platforms. Their value is strongest when objective measurements complement neurological examinations and patient-reported outcomes rather than attempting to replace clinical judgment.

Adoption is being shaped by the need for more frequent observation between appointments, greater emphasis on individualized treatment, and improved management of fluctuating symptoms. Important considerations include measurement validity, usability for people with motor or cognitive impairment, data privacy, interoperability, reimbursement, and equitable access.

360iResearch introduction

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Product Type

    • Non-Wearable Devices
    • Wearable Devices
    View chapter
  2. Chapter 8 Technology

    • Data Analysis Technology
    • Sensor Technology
    View chapter
  3. Chapter 9 End User

    • Home Care Settings
    • Hospitals And Clinics
    • Research Institutes
    View chapter

From Episodic Visits to Continuous, Patient-Centered Monitoring

Parkinson’s monitoring is shifting from predominantly episodic clinic assessment toward repeated measurements collected in homes and everyday environments. This transition can reveal changes that are difficult to capture during a short examination, including medication-related fluctuations, gait instability, dyskinesia, freezing episodes, sleep disruption, and changes in activity patterns.

The landscape is also becoming more multidisciplinary. Neurologists, movement-disorder specialists, rehabilitation professionals, nurses, caregivers, and patients increasingly need shared, interpretable information. Successful implementation therefore depends on clinically meaningful endpoints, simple workflows, technical support, and clear escalation pathways when measurements suggest deterioration or safety risk.

Artificial Intelligence Improves Signal Interpretation but Requires Clinical Oversight

Artificial intelligence can help process high-frequency movement, voice, typing, sleep, and activity data; identify patterns that may warrant review; and reduce the burden of manually interpreting longitudinal records. Machine-learning approaches may also support personalized baselines, anomaly detection, symptom classification, and prioritization of clinically relevant events.

However, algorithmic performance can vary with device placement, adherence, age, disease stage, medication state, comorbidities, and population representation. Leaders should require transparent validation, clinically relevant performance measures, monitoring for bias and drift, explainable outputs, cybersecurity controls, and human review before AI-generated findings influence treatment decisions. AI should function as decision support, not as an autonomous diagnosis or prescribing mechanism.

Regional Insights: Infrastructure and Care Models Shape Adoption

North America generally benefits from advanced digital-health infrastructure, specialist services, and research activity, while adoption is influenced by reimbursement, regulatory evidence, and integration with electronic health records. Latin America faces uneven access to neurologists, connectivity, and specialized rehabilitation, making low-burden mobile tools and hybrid care models particularly relevant where validation and affordability are addressed.

Europe combines strong public health systems and research networks with varied procurement, privacy, and reimbursement environments. The Middle East is developing digital-health capacity but must account for uneven specialist coverage and differences in care access. Africa’s priorities include affordability, offline functionality, workforce support, and approaches that remain useful where specialist services and reliable connectivity are limited. Asia-Pacific spans highly digitized systems and resource-constrained settings; scalable remote monitoring, local-language design, and integration with primary and community care are important implementation themes.

Group Insights: Policy Alignment and Interoperability Are Central

ASEAN markets vary widely in digital infrastructure, specialist availability, language, and regulatory maturity, so interoperable and adaptable tools are more practical than one-size-fits-all deployments. BRICS countries have substantial variation in healthcare capacity and geography, increasing the importance of affordability, local validation, and remote-care pathways. European Union implementation must align with stringent data-protection, medical-device, and health-technology requirements while supporting cross-border interoperability.

G7 settings often have stronger research and clinical infrastructure but still face fragmented workflows, reimbursement questions, and aging populations. GCC countries can leverage concentrated healthcare investment and connected urban systems, while ensuring inclusion beyond major centers. NATO members represent diverse health systems; collaboration on cybersecurity, resilience, standards, and emergency continuity can strengthen trust in connected monitoring without implying uniform procurement or clinical practice.

Country Insights: Diverse Health-System Conditions Require Local Design

Australia and Canada must address dispersed populations and specialist-access barriers, making telehealth-compatible monitoring and strong privacy practices important. Brazil, Mexico, India, and Russia face substantial geographic and socioeconomic diversity; practical deployment should emphasize affordability, regional validation, workforce training, and functionality under variable connectivity. China, Japan, and South Korea have strong technology capabilities but require careful alignment with national regulatory, data-governance, and clinical workflows.

France, Germany, Italy, Spain, and the United Kingdom have established neurological services and public-sector health structures, yet adoption depends on evidence, procurement, interoperability, and reimbursement pathways that differ by jurisdiction. Across the United States, implementation is shaped by fragmented delivery, payer requirements, regulatory oversight, and the need to integrate measurements into clinician workflows. In every country, patient consent, caregiver involvement, accessibility, and clinically validated use cases should guide deployment.

Recommendations for Leaders: Validate, Integrate, and Design for Real-World Use

Leaders should begin with clearly defined clinical decisions: identifying medication fluctuations, supporting rehabilitation, monitoring falls risk, or improving follow-up between visits. Select devices using validated endpoints, transparent accuracy information, patient usability testing, battery and connectivity reliability, and documented cybersecurity controls. Pilot programs should measure adherence, data completeness, clinician workload, patient experience, safety events, and whether results change care appropriately.

Organizations should establish governance for consent, data ownership, retention, access, algorithm updates, and escalation. Integrate outputs into existing clinical systems rather than creating parallel dashboards, and provide training for clinicians and patients. Partnerships with patient groups and caregivers can improve accessibility, while evaluation across age, sex, ethnicity, disease stage, language, disability, and socioeconomic circumstances can identify inequities before broader implementation.

Research Methodology: Evidence-Led Assessment of Monitoring Technologies

This executive summary uses a structured review framework focused on Parkinson’s disease monitoring devices and their clinical implementation context. The assessment considers peer-reviewed evidence, clinical guidance, regulatory principles, health-system documentation, digital-health standards, and publicly documented technology characteristics. Evidence is interpreted according to study design, population, measurement validity, comparator, duration, adherence, clinical relevance, and applicability to routine care.

Regional, group, and country comparisons are qualitative and reflect differences in health-system organization, specialist access, digital infrastructure, privacy requirements, reimbursement, and implementation capacity. Claims are limited to established, verifiable themes. Device performance and AI capabilities should be confirmed against current regulatory documentation and independent clinical validation before procurement or clinical use.

Conclusion: Clinical Utility Must Lead Technology Adoption

Parkinson’s disease monitoring devices can strengthen care by extending observation beyond the clinic and helping teams understand symptoms in daily life. Their impact depends less on data volume than on reliable measurements, meaningful interpretation, secure systems, and workflows that convert findings into timely, patient-centered action.

The most durable strategies combine validated technology with clinical oversight, equitable access, interoperable infrastructure, and continuous evaluation. As AI and remote monitoring mature, leaders should prioritize evidence, transparency, usability, and trust so that digital measurement complements-not replaces-the therapeutic relationship and professional neurological assessment.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Parkinson's Disease Monitoring Device Market, by Product Type
    1. 7.1Introduction
    2. 7.2Non-Wearable Devices
      1. 7.2.1Mobile Apps
      2. 7.2.2Stationary Systems
      3. 7.2.3Tabletop Devices
    3. 7.3Wearable Devices
      1. 7.3.1Footwear Wearables
      2. 7.3.2Implantable Devices
        1. 7.3.2.1Deep Brain Stimulation
        2. 7.3.2.2Neurostimulators
      3. 7.3.3Wrist-Worn Wearables
        1. 7.3.3.1Fitness Bands
        2. 7.3.3.2Smart Watches
  8. 8.Parkinson's Disease Monitoring Device Market, by Technology
    1. 8.1Introduction
    2. 8.2Data Analysis Technology
      1. 8.2.1Ai Algorithms
      2. 8.2.2Machine Learning
    3. 8.3Sensor Technology
      1. 8.3.1Accelerometers
      2. 8.3.2Emg Sensors
      3. 8.3.3Gyroscopes
  9. 9.Parkinson's Disease Monitoring Device Market, by End User
    1. 9.1Introduction
    2. 9.2Home Care Settings
      1. 9.2.1Assisted Living Facilities
      2. 9.2.2Patient Homes
    3. 9.3Hospitals And Clinics
      1. 9.3.1General Hospitals
      2. 9.3.2Neurology Clinics
    4. 9.4Research Institutes
      1. 9.4.1Biotech Firms
      2. 9.4.2Universities
  10. 10.Parkinson's Disease Monitoring Device Market, by Distribution Channel
    1. 10.1Introduction
    2. 10.2Offline Sales
      1. 10.2.1Hospital Sales
      2. 10.2.2Specialty Stores
    3. 10.3Online Sales
      1. 10.3.1Direct Sales
      2. 10.3.2Third Party Retailers
  11. 11.Parkinson's Disease Monitoring Device Market, by Region
    1. 11.1Introduction
    2. 11.2Asia-Pacific
    3. 11.3North America
    4. 11.4Latin America
    5. 11.5Europe
    6. 11.6Middle East
    7. 11.7Africa
  12. 12.Parkinson's Disease Monitoring Device Market, by Group
    1. 12.1Introduction
    2. 12.2ASEAN
    3. 12.3GCC
    4. 12.4European Union
    5. 12.5BRICS
    6. 12.6G7
    7. 12.7NATO
  13. 13.Parkinson's Disease Monitoring Device Market, by Country
    1. 13.1Introduction
    2. 13.2United States
    3. 13.3Canada
    4. 13.4Mexico
    5. 13.5Brazil
    6. 13.6United Kingdom
    7. 13.7Germany
    8. 13.8France
    9. 13.9Russia
    10. 13.10Italy
    11. 13.11Spain
    12. 13.12China
    13. 13.13India
    14. 13.14Japan
    15. 13.15Australia
    16. 13.16South Korea
  14. 14.Competitive Landscape
    1. 14.1Market Share Analysis, 2025
    2. 14.2Market Concentration Analysis, 2025
      1. 14.2.1Concentration Ratio (CR)
      2. 14.2.2Herfindahl Hirschman Index (HHI)
    3. 14.3Recent Developments & Impact Analysis, 2025
    4. 14.4Product Portfolio Analysis, 2025
    5. 14.5Benchmarking Analysis, 2025
  15. 15.Company Profiles
    1. 15.1Abbott Laboratories
    2. 15.2Biogen Inc.
    3. 15.3BlueSky Medical Group
    4. 15.4Boston Scientific Corporation
    5. 15.5Byteflies NV
    6. 15.6Clario
    7. 15.7Cleveland Medical Devices Inc.
    8. 15.8Gait Up SA
    9. 15.9GE Healthcare, Inc.
    10. 15.10Global Data Sciences Inc.
    11. 15.11Great Lakes NeuroTechnologies, Inc.
    12. 15.12Koneksa Health Corporation
    13. 15.13Koninklijke Philips N.V.
    14. 15.14MC10 Inc.
    15. 15.15Medtronic plc
    16. 15.16mHealth Technologies Srl
    17. 15.17NeuroMetrix, Inc.
    18. 15.18PKG Health Ltd.
    19. 15.19Roche Holding AG
    20. 15.20Siemens Healthineers AG
    21. 15.21uMotif Limited
    22. 15.22Verily Life Sciences LLC
  16. 16.Key Experts
Licensesfrom $3,939

Loading the sample request form…